<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199602</url>
  </required_header>
  <id_info>
    <org_study_id>I99006</org_study_id>
    <nct_id>NCT00199602</nct_id>
  </id_info>
  <brief_title>Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients</brief_title>
  <official_title>Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative
      3-arms of 140 patients (i.e. 420 total patients).

      Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1999</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the prevalence of symptomatic or asymptomatic deep venous thrombosis in cancer patients with implantable device for central venous access with or without prophylaxis :</measure>
    <time_frame>Day90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Low molecular weight Heparin (LMWH) 2500 U anti-XA/day or Warfarine 1 mg/day during the first line of chemotherapy</measure>
    <time_frame>Day90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Detection of asymptomatic thrombosis related to implantable device estimated by a systematic echo-doppler. -</measure>
    <time_frame>Day90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Frequency of other symptomatic venous thromboembolic events between 3 groups.</measure>
    <time_frame>J0, J1, J21, J42, J63 and J90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of thrombosis prophylaxis by LMWH with warfarin at low dose</measure>
    <time_frame>Day90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Costs in the 3 strategies</measure>
    <time_frame>J90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Tumoral response to chemotherapy in the 3 groups.</measure>
    <time_frame>Day90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Overall survival in each group.</measure>
    <time_frame>Day90</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>lack of drug prophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HBPM 2500 UI anti Xa in one subcutaneous injection per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarine 1mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarine - low molecular heparin</intervention_name>
    <arm_group_label>HBPM 2500 UI anti Xa in one subcutaneous injection per day</arm_group_label>
    <arm_group_label>warfarine 1mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First line chemotherapy for solid tumor with:

          -  Metastatic disease or

          -  Involved nodes or

          -  Unresectable tumor

          -  Indication for Implantable device for central venous access

          -  Potential survival &gt; 3 months

          -  ECOG performance status 0 to 2 (WHO)

          -  Age between 18 and 75 years.

          -  Social security guaranteed

          -  Normal laboratory assessments (platelets&gt; 100000/mm3, TP 60%, spontaneous TCA with
             M/T&lt;1.5, TGO and TGP &lt; 2xN, serum creatinin&lt;120µmol/l)

          -  Informed consent signed

        Exclusion Criteria:

          -  Inability to understand informed consent or interfering with compliance for treatment
             or protocol Anti-coagulant treatment -related criteria

          -  Acute infectious endocarditis

          -  History related with heparin allergy or thrombopenia due to heparin

          -  Uncontrolled high blood pressure (systolic blood pressure &gt;180 mm Hg and/or diastolic
             blood pressure &gt;110 mm Hg)

          -  Hemorrhagic syndrome ongoing

          -  Patient with platelet inhibitors treatment

          -  Chronic, daily treatment with anti-coagulant therapy (LMWH or AVK), use as preventive
             or curative level

          -  Patient with liver failure (TP&lt;60%) or renal insufficiency (creatinin clearance&lt; 20
             ml/mn)

          -  Women with pregnancy and lactating Pathology-related criteria

          -  deep venous thrombosis history or pulmonary embolism (&lt; 6 months)

          -  Clinical suspicious of brain metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole TUBIANA-MATHIEU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncologie Médicale</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Vénat-Bouvet L, Labourey JL, Martin J, Slaouti P, Tubiana-Mathieu N. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol. 2013 Jul;72(1):65-73. doi: 10.1007/s00280-013-2169-y. Epub 2013 May 1.</citation>
    <PMID>23636449</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

